Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: A Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer

Investigational New Drugs

Volumn 20, Issue 4, 2002, Pages 419-424

  Leichman, Cynthia G ^a   Chansky, Kari ^b   Macdonald, John S ^c   Doukas, Michael A ^d   Budd, G Thomas ^e   Giguere, Jeffrey K ^f   Abbruzzese, James L ^g  

^a Desert Comprehensive Cancer Center   (United States)

^b Statistical Center   (United States)

^c ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Greenville CCOP   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Colorectal cancer; Dehydrogenase; Dihydropyrimidine

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTINEOPLASTIC PROTOCOLS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; SOUTHWESTERN UNITED STATES; SURVIVAL RATE; TREATMENT FAILURE; URACIL;

EID: 0036828668     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020662113061     Document Type: Article

References (14)

1. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Maillard JA, Laurie JA, Tschetter LK, Wiesenfield M: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS: Phase II study of 5-FU and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13(6):1303-1311, 1995
4. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
5. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller D, Arbuck SG, Weiner LM, Mayer RJ, Bebson AB III: Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Easter Cooperative Oncology Group/Cancer and Leukemia Group B study. J Clin Oncol 19:2413-2421, 2001.
6. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha Wi, Pazdur R, Weiand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
7. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillard JA: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
8. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47:2203-2206, 1987
9. Shousong C, Yousef MR, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
10. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Onocl 14:3085-3096, 1996
11. Schilsky RL, Hohneker JA, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA III: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450-1457, 1998
12. Burroughs Wellcome: 776C85: Updated (3/95) Summary of Non-Clinical and Clinical (Phase 1) Data
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter, J. Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
14. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Gaudreault J, Lieberman G, Kabbinavar F: A Randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19:939, 2000